Skip to main content
0
Introduction
Aims
Methods
Results
Conclusions
References
Disclosures
Slide deck
Plain language summary
Overview with audio
Aim
To assess FVC decline and adverse events in patients treated with nintedanib in SENSCIS-ON.
×
Notice
This website is intended for healthcare professionals only.
Modal title
You are navigating away from the website. Are you sure you want to proceed?
